Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28735742 | 0.94 | MCHR1 (0.41) | KMT2AALDH1A1LMNASMN1; SMN2L3MBTL3 | |
| SCHEMBL4114791 | 0.94 | MCHR1 (0.41) | KMT2AALDH1A1LMNASMN1; SMN2L3MBTL3 | |
| SCHEMBL6435389 | 0.90 | KMT2A (0.43) | KMT2AALDH1A1LMNASMN1; SMN2L3MBTL3 | |
| SCHEMBL6418241 | 0.89 | KMT2A (0.45) | KMT2AALDH1A1LMNASMN1; SMN2L3MBTL3 | |
| SCHEMBL27564719 | 0.87 | ALDH1A1 (0.44) | KMT2AALDH1A1LMNASMN1; SMN2L3MBTL3 | |
| SCHEMBL6414922 | 0.84 | L3MBTL3 (0.43) | KMT2AALDH1A1LMNASMN1; SMN2L3MBTL3 | |
| SCHEMBL21464535 | 0.82 | L3MBTL3 (0.50) | L3MBTL3MCHR1L3MBTL1KDM1AMAOA | |
| SCHEMBL2883536 | 0.82 | L3MBTL3 (0.50) | L3MBTL3MCHR1L3MBTL1KDM1AMAOA | |
| SCHEMBL2883532 | 0.82 | L3MBTL3 (0.50) | L3MBTL3MCHR1L3MBTL1KDM1AMAOA | |
| SCHEMBL4489462 | 0.82 | MCHR1 (0.43) | KMT2AL3MBTL3MEN1MCHR1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817281-A1 | N- [(3S)- PYRROLIDIN-3-YL]- BENZAMIDE DERIVATIVES AS MONOAMINE RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-7122683-B2 | Amides useful as monoamine re-uptake inhibitors | PFIZER INC. (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2006056884-A1 | N- [ (3S)- PYRROLIDIN-3-YL]- BENZAMIDE DERIVATIVES AS MONOAMINE RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2006-06-01 | — | — | WO | disclosed |
| US-20060111429-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111429-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | ADRB3, AOC3, HRH4 | KMT2A 3211/4885ALDH1A1 461/4885LMNA 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.